PinnyPeptide

ARA-290 (Cibinetide) vs VIP (Vasoactive Intestinal Peptide)

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

ARA-290 (Cibinetide)

Healing & Recovery

Tissue-protective helix-B fragment of erythropoietin — without the red-blood-cell effects.

Peptide B

VIP (Vasoactive Intestinal Peptide)

Healing & Recovery

Broad neuropeptide with anti-inflammatory, immunomodulatory, and vasodilatory activity.

Typical vial

8 mg

Typical dose

2,000-8,000 mcg

Half-life

~2 minutes (plasma); longer functional duration via receptor binding

FDA status

Not FDA approved. In clinical development by Araim Pharmaceu…

Typical vial

5 mg

Typical dose

50-200 (intranasal) mcg

Half-life

~2 minutes (plasma); longer functional duration via tissue distribution

FDA status

Not FDA approved as therapeutic. VIP analog aviptadil receiv…

ARA-290 (Cibinetide) effects

  • Activates the innate repair receptor (IRR / EpoR-βcR heterodimer)
  • Reduces tissue inflammation in injury models
  • Promotes axonal regeneration in small-fiber neuropathy
  • Does NOT raise hemoglobin or platelet count
  • Tissue-protective in ischemia-reperfusion models

VIP (Vasoactive Intestinal Peptide) effects

  • Vasodilation and smooth-muscle relaxation
  • Broad anti-inflammatory effects via VPAC1/VPAC2
  • Immunomodulatory: shifts T-helper balance toward Th2/regulatory
  • Circadian rhythm organization (suprachiasmatic nucleus activity)
  • Lung-protective effects in ARDS and pulmonary hypertension models
  • Used clinically in CIRS / biotoxin-illness recovery protocols

ARA-290 (Cibinetide) side effects

  • Generally well-tolerated in clinical trials
  • Injection-site reactions (mild)
  • No erythropoietic effects (deliberate design)
  • Long-term safety with chronic dosing still being characterized

VIP (Vasoactive Intestinal Peptide) side effects

  • Hypotension and flushing (especially with rapid IV)
  • Tachycardia
  • Headache
  • GI effects (cramping, diarrhea at high doses)
  • Intranasal: occasional nasal irritation

ARA-290 (Cibinetide) dosing ranges

Small-fiber neuropathy / nerve healing

2-8 mg · Once daily (SubQ) · 4-12 weeks per cycle

General tissue protection research

1-4 mg · Daily or alternate-day · Per research protocol

VIP (Vasoactive Intestinal Peptide) dosing ranges

Intranasal CIRS protocol (off-label)

50 mcg · 4 sprays daily · Per Shoemaker protocol; months to years for full restoration

Research / immunomodulation

Variable per protocol · Per protocol · Per protocol

Full ARA-290 (Cibinetide) guide → Full VIP (Vasoactive Intestinal Peptide) guide →

ARA-290 (Cibinetide) vs VIP (Vasoactive Intestinal Peptide) — common questions

What is the difference between ARA-290 (Cibinetide) and VIP (Vasoactive Intestinal Peptide)?

ARA-290 (Cibinetide): Tissue-protective helix-B fragment of erythropoietin — without the red-blood-cell effects. Typical dose 2,000-8,000 mcg. VIP (Vasoactive Intestinal Peptide): Broad neuropeptide with anti-inflammatory, immunomodulatory, and vasodilatory activity. Typical dose 50-200 (intranasal) mcg. Both fall under the Healing & Recovery category.

Can you stack ARA-290 (Cibinetide) and VIP (Vasoactive Intestinal Peptide)?

Stacking ARA-290 (Cibinetide) with VIP (Vasoactive Intestinal Peptide) is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, ARA-290 (Cibinetide) or VIP (Vasoactive Intestinal Peptide)?

ARA-290 (Cibinetide) is typically dosed: Once daily (SubQ) for Small-fiber neuropathy / nerve healing; Daily or alternate-day for General tissue protection research. VIP (Vasoactive Intestinal Peptide) is typically dosed: 4 sprays daily for Intranasal CIRS protocol (off-label); Per protocol for Research / immunomodulation.

Are ARA-290 (Cibinetide) and VIP (Vasoactive Intestinal Peptide) FDA approved?

ARA-290 (Cibinetide): Not FDA approved. In clinical development by Araim Pharmaceuticals. Granted orphan drug designation for sarcoidosis-related conditions. VIP (Vasoactive Intestinal Peptide): Not FDA approved as therapeutic. VIP analog aviptadil received Emergency Use Authorization consideration for COVID-19 ARDS but not full approval.

Related peptide comparisons

ara-290 vs b7-33ara-290 vs bpc-157ara-290 vs kpvara-290 vs tb-500ara-290 vs tb-500-frag-17-23bpc-157 vs vip

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free